Medable Pitch Deck: Slide-by-Slide Breakdown

Executive Summary: The $304M Series D Narrative

Medable’s 2022 pitch deck is a textbook example of a Series D presentation. At this stage, investors are looking for dominant market positioning, proven enterprise scale, and a clear path to becoming an industry standard. Medable delivers this by framing the entire clinical trial industry as an antiquated system that was forced to modernize by the global pandemic. The deck uses a mix of high-level visionary goals and dense, operational workflows to prove that they aren't just a software vendor, but a critical infrastructure layer for drug development.

Slide 1: Title and Vision

The deck opens with a bold claim: "Leaders in Patient-Centered Drug Development." The imagery features an elderly woman using a pulse oximeter and a smartphone, immediately grounding the high-tech 'Unified Cloud' pitch in a real-world patient use case. This visual reinforces the 'patient-centered' theme that recurs throughout the deck.

Slide 2: The Leading Team

Medable leads with its team, emphasizing the medical credentials of its CEO, Michelle Longmire, MD . The slide features six key executives, including the CTO, COO, and leads for strategy, business development, and product. A small footnote indicates that the COO is no longer at Medable, a piece of transparency that is rare in pitch decks but necessary for late-stage due diligence.

Slide 3: The Mission and the 'Broken' Status Quo

This is the 'Problem' slide. Medable identifies four staggering statistics to prove clinical drug development is inefficient: 3% of eligible patients participate, $2.6B cost per approval, 12Y time to approval, and <7% diversity in participants. By quantifying the pain, Medable sets the stage for a solution that promises to 'enable effective therapies to reach patients faster.'

Slide 4: The COVID-19 Catalyst

Slide 4 is the 'Why Now?' slide. It contrasts the 'Prior to 2020' site-based research model with the '2020 and Beyond' decentralized model. It notes that 37% of sites fail to meet enrollment targets and 35% of patients drop out due to lack of patient-centric design. Medable claims that in the new era, enrollment has accelerated 3x across therapeutic areas.

Slide 5: Positioned to Win

This slide introduces the product ecosystem. It highlights three primary interfaces: the Patient app & connected devices , the Clinician app , and the Study management app . It lists four competitive advantages: a purpose-built offering, a clean slate strategy, being nimble and fast, and being leaders in the space.

Slide 6: Digital & Decentralized Traction

This is the 'Traction' slide, and it is arguably the strongest in the deck. Medable claims to be trusted by 5 of the top 10 pharmaceutical companies and 5 of the top 7 CROs . The metrics are equally impressive: 50+ Clients , 100% Client Retention , 300% Growth in Revenue , and 1M+ Patients .

Slide 7: Global Capability

To serve 'Big Pharma,' a platform must be global. Slide 7 highlights Medable's reach: 125+ Global DCTs (Decentralized Clinical Trials), 60+ Countries , and 60+ Languages . It also mentions compliance with FDA CFR21 Part 11, HIPAA, and GDPR , which are non-negotiable requirements in healthcare technology.

Slide 8 & 9: The Unified Cloud Platform

These slides provide a technical and functional deep dive. Slide 8 shows a complex diagram of the 'Unified Cloud Platform,' illustrating how data flows from sensors and wearables through an automation and AI layer into a data warehouse. Slide 9 focuses on the user experience, describing the interface as 'Flexible, Dynamic, Engaging' and listing features like eConsent, TeleVisits, and eSource .

Slide 10: The Participant Journey

This slide maps out the entire lifecycle of a clinical trial participant on the Medable platform. It starts with Recruitment via Referral, Social Media or Clinic and moves through Eligibility screening, TeleConsent, eDiary, TeleVisits, and Real Time Data Capture , ending with Data Lock . This proves the platform handles the 'end-to-end' journey, not just a single niche task.

Slides 11-16: The Redacted Financials

These slides represent the meat of a Series D deck: Subscription Revenue (Slide 11), Committed Annual Recurring Revenue (Slide 12), Bookings (Slide 13), KPIs (Slide 14), ROI in product (Slide 15), and the 2021 Operating Plan (Slide 16). In this version of the deck, the data is hidden behind purple blocks. However, slide 14 is still valuable for founders as it lists the exact metrics Medable tracks, including Net Revenue Retention , Human Capital Efficiency (ARR per headcount), and Blended CAC Ratio .

Slide 17: Radically Advancing Clinical Research

The deck concludes by returning to high-level impact. It categorizes its success into four buckets: Access & Diversity , Value to Patients , Speed , and Driving Industry Change . It specifically mentions measuring success through Net Promoter Score (NPS) and patient satisfaction.

What Medable Does Well

The Medable deck excels at Social Proof . For a Series D company, the most important metric is often 'who else is using this?' By naming the percentage of top-tier pharma companies and CROs they have captured, they create a sense of inevitability. If the industry leaders are using Medable, the smaller players must follow suit to remain competitive.

Furthermore, the deck does an excellent job of Contextualizing the Market . They don't just say they have a good product; they argue that the world changed in 2020 and their product is the only one built for the new reality. This 'New World' narrative is a powerful way to justify high valuations and rapid growth expectations.

What is Missing from the Deck

While the redactions hide the specific financials, there are a few structural omissions worth noting:

Competitive Landscape: The deck claims Medable is 'leading,' but it does not show a traditional competitor matrix. In a crowded health-tech space, seeing how they differentiate against legacy players like Medidata or newer entrants would be valuable. · The 'Ask': There is no slide explicitly stating how much they are raising or what the use of funds will be. While this is often handled in a separate document or a verbal conversation at the Series D level, its absence makes the deck feel more like a corporate brochure than a fundraising tool. · Unit Economics: While Slide 14 lists 'Blended CAC Ratio' as a KPI, the deck doesn't explain the underlying unit economics of a single trial or a single enterprise contract.

What Founders Should Copy

Founders should study Slide 10 (The Participant Journey) . Many startups struggle to explain exactly how their product works in practice. Mapping out the user journey step-by-step, with screenshots of the mobile and desktop interfaces, makes a complex cloud platform feel tangible and easy to understand.

Additionally, the KPI list on Slide 14 is a gold standard for SaaS companies. Even if you aren't at Series D, tracking metrics like 'Human Capital Efficiency' (ARR/Headcount) and 'Organic ARR Growth' shows investors that you have a sophisticated understanding of how to scale a business, not just how to build a product.

Final Verdict: This deck is designed to prove that Medable is the 'winner' in the decentralized clinical trial category. It uses massive enterprise logos and a global scale narrative to make the investment feel like a safe bet on a dominant market leader.